Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study
Jin Joo Park, Sang Eun Lee, Hyun‐Jai Cho, Jin‐Oh Choi, Byung‐Su Yoo, Seok‐Min Kang, Hsiang-Chi Wang, Sue Lee, Dong‐Ju Choi
Abstract
Background and Objectives: Differences in drug prescriptions exist between clinical trials and real-world practice. We evaluated the real-world treatment patterns of sacubitril/valsartan in Korean patients with heart failure (HF). Methods: In this retrospective, multicenter cohort study, 600 patients with HF with reduced left-ventricular ejection fraction (LVEF <40%) with ≥1 sacubitril/valsartan prescription were identified by reviewing patient-level medical records at six academic tertiary hospitals in Korea between February 2017 and April 2019. Results: at baseline and follow-up, respectively. Conclusions: In real-world practice, 95% patients started with low and moderate doses of sacubitril/valsartan. Many patients experienced dose up-titration during follow-up; 30% reached the target dose. Cardiac reverse remodelling was reflected by a profound NT-proBNP level and LV size reduction, and LVEF increment. This study confirms the gap in treatment patterns between clinical trials and real-world practice.